dual agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Polymyalgia rheumatica (PMR) is a systemic inflammatory disease characterized by pain or stiffness, usually in the neck, shoulders, upper arms, and hips, but which may occur all over the body. Almost all cases occur in people age 50 or older. Pain and stiffness of PMR is worse in the morning and improves throughout the day, but these symptoms frequently persist to some extent throughout the day and into the evening. People who have polymyalgia rheumatica may also have temporal arteritis (giant cell arteritis), an inflammation of blood vessels in the face which can cause blindness if not treated quickly. The pain and stiffness can result in a lowered quality of life, and can lead to depression. The exact cause of PMR, including whether or not it may be an autoimmune disease, is unclear. Persons of Northern European descent are at greater risk. There is no definitive laboratory test, but C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) can be useful as non-specific markers of systemic inflammation. PMR is usually treated with corticosteroids taken by mouth. Most people need to continue the corticosteroid treatment for two to three years. PMR sometimes goes away on its own in a year or two, but medications and self-care measures (e.g., eating the recommended amount of fruits and vegetables) can improve the rate of recovery. PMR was first established as a distinct disease in 1966 by a case report on 11 patients at Mount Sinai Hospital in New York City. It takes its name from the Greek word Πολυμυαλγία polymyalgia, which means "pain in many muscles".
== Use == The first publication on vinylene carbonate described its Diels-Alder reaction using the example of its addition reaction with 2,3-dimethylbutadiene to a bicyclic carbonate and subsequent hydrolysis to cis-4,5-dihydroxy-1,2-cyclohexene:
Gleason (1938), music critic for the San Francisco Chronicle and co-founder of Rolling Stone Eugene Williams (1938), jazz critic, founder of Jazz Information Allan Temko (1947), architecture critic of the San Francisco Chronicle and winner of the Pulitzer Prize for Criticism Andrew Sarris (1951), film critic Martin Gottfried (1955), critic, author, and biographer Donald Kuspit (1955), art critic Morris Dickstein (1961), cultural critic and professor at The Graduate Center, CUNY David Denby (1965), film critic for The New Yorker Michael Feingold (1966), lead theater critic for The Village Voice Martin Filler (1970), architecture critic Gerrit Henry (1972), art critic, author, poet Jed Perl (1972), art critic; son of Nobel laureate Martin Lewis Perl GSAS '55 Lucy Sante (1976), literary critic Tim Page (1979), music critic of The Washington Post and winner of the Pulitzer Prize for Criticism Jonathan Beller (1985), cultural critic, professor at Pratt Institute Michael Riedel (1989), theater critic for New York Post Ben Ratliff (1990), journalist and music critic Neil Strauss (1991), music critic and best-selling author Justin Shubow (1999), architectural critic, former chairman and member of the United States Commission of Fine Arts Helena Andrews (2002), pop culture critic
Sources: en.wikipedia.org
Most paleontologists have always accepted that Tyrannosaurus was an active predator and, like most large carnivores, would also opportunistically scavenge. By far the largest carnivore in its environment, T. rex was most likely an apex predator, preying upon hadrosaurs, armored herbivores like ceratopsians and ankylosaurs, and possibly sauropods (such as Alamosaurus). Enamel δ44/42Ca values also suggest the possibility that T. rex occasionally fed on carcasses of marine reptiles and fish washed up on the shores of the Western Interior Seaway. A study in 2012 by Karl Bates and Peter Falkingham found that Tyrannosaurus had the most powerful bite of any terrestrial animal that has ever lived, finding an adult Tyrannosaurus could have exerted 35,000 to 57,000 N (7,868 to 12,814 lbf) of force in the back teeth. Even higher estimates were made by Mason B. Meers in 2003. This allowed it to crush bones during repetitive biting and fully consume the carcasses of large dinosaurs. Stephan Lautenschlager and colleagues calculated that Tyrannosaurus was capable of a maximum jaw gape of around 80 degrees, a necessary adaptation for a wide range of jaw angles to power the creature's strong bite. A discredited fringe hypothesis that was never seriously considered was that Tyrannosaurus was an obligate scavenger. The argument originated in a 1917 study by Lambe which argued that large theropods were pure scavengers because Gorgosaurus teeth showed hardly any wear. This argument disregarded the fact that theropods rapidly replaced their teeth.
methylarsonite + glutathione disulfide + H2O Thus, the two substrates of this enzyme are methylarsonate and glutathione, whereas its 3 products are methylarsonite, glutathione disulfide, and H2O. This enzyme belongs to the family of oxidoreductases, specifically those acting on phosphorus or arsenic in donor with disulfide as acceptor. The systematic name of this enzyme class is gluthathione:methylarsonate oxidoreductase. This enzyme is also called MMA(V) reductase.
Attempts by the peasants to take over land were usually resisted by the authorities. On 28 October 1949 in Melissa police opened fire on peasants who had occupied the land of a local baron, killing three men as they attempted to flee. Between 1949 and 1966 another migration wave peaked in 1957 as some 38,090 Calabrians left.
Sources: en.wikipedia.org
=== Water === Moscow has two passenger terminals (South River Terminal and North River Terminal) on the Moskva River. There are regular ship routes and cruises along the Moskva and Oka rivers, which are used mostly for entertainment. The North River Terminal, built in 1937, is the main hub for long-range river routes. In addition, three freight ports serve Moscow. Moscow is connected via the Moscow Canal to Russia's Unified Deep Water System, a large system of canals and rivers in European Russia. This system gives the city water access to five seas: the White Sea, Baltic Sea, Caspian Sea, Sea of Azov, and the Black Sea. For this reason, Moscow is sometimes called the "port of the five seas" (Russian: порт пяти морей).
The substrates of this enzyme are glutathione and cystine. Its products are glutathione disulfide and cysteine. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with a disulfide as acceptor. The systematic name of this enzyme class is glutathione:cystine oxidoreductase. Other names in common use include GSH-cystine transhydrogenase, and NADPH-dependent GSH-cystine transhydrogenase. This enzyme participates in cysteine metabolism and glutathione metabolism.
Melanocortin 5 receptor (MC5R) is a protein that in humans is encoded by the MC5R gene. It is located on the chromosome 18 in the human genome. When the MC5R was disrupted in transgenic mice, it induced disruption of their exocrine glands and resulted in decreased production of sebum.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.